Pipeline Breadth, Market Conditions, and Path Dependence: What Predicts Biotech Financing Valuations Beyond Comparable Transaction Filters

Muralitharan (2026) established that the three standard comparable transaction filters-clinical stage, therapeutic indication, and drug modality-explain less than 9% of biotech financing valuation variance. This paper asks the natural follow-up: what observable characteristics do predict pre-money valuations? I systematically screen 14 candidate variables across five domains-company capital history, clinical pipeline breadth, regulatory milestones, market conditions, and firm characteristics-and classify each by its endogeneity relationship to the outcome. Using 3,053 biotech financing transactions from 2013 to 2026, I find that five pre-deal, non-circular observables-active clinical trial count, max planned enrollment, XBI index level, XBI 90-day trailing return, and FDA breakthrough therapy designation-collectively achieve a cross-validated ???? 2 of 0.186, more than double the comparable transaction model. Adding the company's prior financing valuation increases cross-validated ???? 2 to 0.600, revealing that biotech pricing is strongly path-dependent: the single most powerful predictor is what the company was valued at in its previous financing round. Crucially, adding clinical stage, therapeutic indication, and drug modality dummies to any specification produces near-zero incremental cross-validated ???? 2 (Model 5 to Model 6: +0.004). These findings suggest that biotech financing valuations are driven by the scale of clinical programs, prevailing market conditions, and valuation momentum-not by the categorical labels that comparable transaction filters employ. Because disclosed valuations overwhelmingly derive from IPOs and follow-on offerings, these results primarily characterize public biotech financing; generalization to private venture rounds requires further investigation.